AstraZeneca’s COVID-19 vaccine candidate, AZD1222, met the primary efficacy endpoint in preventing COVID-19. Analysis included data from COV002 Phase II/III trial in the UK and COV 0003 Phase III trial in Brazil, involving 23,000 participants. Two different dosing regimens were assessed and demonstrated efficacy. One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose followed by a full dose at least one month apart, and another dosing regimen (n=8,8...